research Prostate Specific Antigen Levels in Diabetic and Non-Diabetic Men from the 2001–2002 National Health and Nutrition Examination Survey
Long-term diabetes is linked to lower prostate cancer risk.
Search
for
Sort by
Research
990-1000 / 1000+ results research IMPLICAÇÕES DA TOMA CRÓNICA DA FINASTERIDE PARA A ALOPÉCIA ANDROGENÉTICA NO CARCINOMA DA PRÓSTATA
Chronic use of 1 mg/day finasteride for hair loss may delay prostate cancer diagnosis by lowering PSA levels.
research Role of serum androgens and prostate-specific antigen levels in males with androgenetic alopecia
Higher serum androgens contribute to male pattern baldness.
research Association between degrees of alopecia and prostate specific antigen level in men with androgenetic alopecia
No link found between hair loss severity and PSA levels in men.
research P152 : Association between degrees of alopecia and prostate specific antigen level in men with androgenetic alopecia
No link between hair loss severity and PSA levels in men.
research Faculty Opinions recommendation of Androgenetic alopecia and risk of prostate cancer: a systematic review and meta-analysis.
Hair loss at the top of the head is linked to prostate cancer, but other types of hair loss are not.
research Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor
Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.
research Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5α-Reductase Activity and Androgen Receptor Content*
A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.
research The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression
5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
research Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology
Tamsulosin for enlarged prostate may increase the risk of severe low blood pressure, especially when starting or restarting the medication.